2-23-04

Express Mail Label No.: EV 392154180 US Quate of Deposit: February 20, 2004

Attorney Docket No.: 18427-001 CON2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PLICANTS:

Sarvetnick, et al.

SERIAL

10/672,685

**EXAMINER:** 

Not yet assigned

NUMBER:

FILING DATE:

September 26, 2003

ART UNIT:

1641

FOR:

PANCREATIC PROGENITOR CELLS AND METHODS FOR

ISOLATING THE SAME

**Mail Stop IDS** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Information Disclosure Statement (1 page), in duplicate;
- 2. Modified Form 1449/PTO (2 pages), in duplicate; and
- 3. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311, Ref. No. 18427-001 CON2. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

(vor R. Elrifi, Reg( No. 39,52

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241 Customer No. 30623

Dated: February 20, 2004

TRA 1887968v1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Sarvetnick, et al.

SERIAL

10/672,685

**EXAMINER:** 

Not yet assigned

NUMBER:

FILING DATE:

September 26, 2003

ART UNIT:

1641

FOR:

PANCREATIC PROGENITOR CELLS AND METHODS FOR ISOLATING

THE SAME

Mail Stop IDS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is believed required. Copies of the references are not provided as they were previously cited and/or submitted to the USPTO in prior applications, Serial No. 09/826,779, filed April 5, 2001, and Serial No. 09/212,531, filed December 16, 1989, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications). Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 18427-001 CON2.

Respectfully submitted,

vor R. Elrifi, Reg No. 39,529

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY and POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241 Customer No. 30623

Dated: February 20, 2004

Express Mail Label No.: EV 392154180 US Date of Deposit: February 20, 2004

Please type a plus sign (+) in this box





Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO						Application Number 10/672,685						
						Filing Date September 26, 2003						
INFORMATION DISCLOSURE					First Named Inventor	Sarvetnick						
STATEMENT BY APPLICANT						Group Art Unit	1641 .					
						Examiner Name Not Yet Assigned						
2 m	(use	•	sheets as r	ecessary)	Lawrence Control				27-001 CON2			
			4 40		U.S.	PATENT DOCUMENTS		CONTROL OF THE		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
Exam Initials	Cite No.			Issue Date	Name of Patentee(s) or Applicant(s)			Class	Sub Class	Filing Date If Appropriate		
	A1	**5,849,989 12/		12/15/98	Edlund			800	2			
	A2	**5,858,973 **6,326,201 B1		01/12/99	Habener, et al.			514	12			
	А3				Fung,	ng, et al.			377	<u> </u>		
							-					
		<u> </u>	***		FOREIG	GN PATENT DOCUMENTS		<b>.</b> E				
Exam Initials	Cite No.	Foreig Office	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)			Date of Publication		Translation Yes No		
	B1	*wo	98/26044		The Regents of The University of California			06/18/98				
	B2	*wo	96/11949		Amgen			04/25/96				
	B3	*WO			Ontoge			12/19/96				
	B4	*WO	98/1624		Amgen, Inc.			04/23/98				
	B5	*EP	0 363 1	25	Hana Biologics, Inc.			04/11/90				
_												
	93.5		`	THER PRIOF	ART - I	NON PATENT LITERATURE DO	CUMEN	TS	3.4 - 2.4 - 3.4 -			
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.										
	C1	*Arnush et al., "Growth factors in the regenerating pancreas of gamma-interferon transgenic mice," Lab. Invest. 74: 985-990 (1996).										
	C2	*Gu é	*Gu et al., "Epithelial cell proliferation and islet neogenesis in IFN-g transgenic mice," Development, 118: 33-46 (1993).									
	СЗ	*Guo	et al., "Ta	*Guo et al., *Targeting expression of keratinocyte growth factor to keratinocytes elicits striking changes in epithelial								
	C4	*!!***	differentiation in transgeic mace," EMBO J., 12: 973-986 (1993).  *Housley et al., "Keratinocyte growth factor induces proliferation of hepatocytes and, epithelial cells throughout the									
	1	reta	sley et al.,	"Keratinocyte	growth fa	1BO J., 12: 973-986 (1993). actor induces proliferation of hep	•		_	•		
	C5	rat g	sley <i>et al.,</i> astrointes yen, <i>et al</i> .,	"Keratinocyte tinal tract," J. "Expression o	growth fa Clin. Inve of keratin	ABO J., 12: 973-986 (1993). actor induces proliferation of hep est., 94: 1764-1777 (1994). ocyte growth factor in embryonic	atocytes	and, ep	ithelial cell	s throughout the		
	C5	rat g *Nguy epith	sley <i>et al.,</i> astrointes yen, <i>et al</i> .,	"Keratinocyte tinal tract," <i>J.</i> "Expression of th and differer	growth fa Clin. Inve of keratin	1BO J., 12: 973-986 (1993). actor induces proliferation of hep est., 94: 1764-1777 (1994).	atocytes	and, ep	ithelial cell	s throughout the		
	C5	rat g *Nguy epith 2109 *Sarv	sley et al., astrointes yen, et al., nelial grow 3-2119 (19 etnick et a	"Keratinocyte tinal tract," J. "Expression of th and differen 196). al., "Insulin-de	growth fa Clin. Invention of keration of the contraction re- contraction of the contraction of the contracti	ABO J., 12: 973-986 (1993).  actor induces proliferation of hepest., 94: 1764-1777 (1994).  ocyte growth factor in embryonic esulting in polycystic kidneys and diabetes mellitus induced in trans	atocytes liver of t other or	and, ep ransgen gan mal	ithelial cell ic mice car formations	s throughout the uses changes in " Oncogene, 12		
		rat g *Nguy epith 2109 *Sarv III M	sley et al., astrointes yen, et al., nelial grow 9-2119 (19 etnick et a HC and in	"Keratinocyte tinal tract," J. "Expression of th and differen 196). al., "Insulin-del terferon-gamr	growth fa Clin. Invention of keration of the contraction of the cont	ABO J., 12: 973-986 (1993).  actor induces proliferation of hep est., 94: 1764-1777 (1994).  ocyte growth factor in embryonic esulting in polycystic kidneys and diabetes mellitus induced in trans 52: 773-782 (1988).	atocytes liver of t d other or sgenic m	and, ep ransgen gan mal ice by e	ithelial celli ic mice car formations ctopic expr	s throughout the uses changes in ," Oncogene, 12 ession of class		
	C6	rat g *Nguy epitt 2109 *Sarv III M *Yi et	sley et al., astrointes yen, et al., nelial grow 9-2119 (19 etnick et a HC and in t al., "Kera 4).	"Keratinocyte tinal tract," J. "Expression of the and differen 196). al., "Insulin-deterferon-gament tinocyte growt	growth faction responds to the contraction responds to the	ABO J., 12: 973-986 (1993). actor induces proliferation of hep est., 94: 1764-1777 (1994). ocyte growth factor in embryonic esulting in polycystic kidneys and diabetes mellitus induced in trans 52: 773-782 (1988).	atocytes liver of t dother or sgenic m ial prolife	and, ep ransgen gan mal ice by e	ithelial cells ic mice car formations ctopic expr	s throughout the uses changes in " Oncogene, 12 ession of class hol., 145: 80-85		
	C6	rat g *Nguy epith 2109 *Sarv III M *Yi et (199 *Pesh	sley et al., astrointes yen, et al., helial grow 9-2119 (19 etnick et a HC and in al., "Kera 4).	"Keratinocyte tinal tract," J. "Expression of the and differen 196).  "Insulin-depterferon-game tinocyte growth Stein, Pancrea	growth facilin. Investigation for the control of th	ABO J., 12: 973-986 (1993). actor induces proliferation of hep est., 94: 1764-1777 (1994). ocyte growth factor in embryonic esulting in polycystic kidneys and diabetes mellitus induced in trans 52: 773-782 (1988). Induces pancreatic ductal epitheliath and Regeneration, Chapter 4,	atocytes liver of t dother or sgenic m ial prolife	and, ep ransgen gan mal ice by e	ithelial cells ic mice car formations ctopic expr	s throughout the uses changes in " Oncogene, 12 ession of class hol., 145: 80-85		
	C6 C7 C8 C9	rat g *Nguy epitt 2109 *Sarv III M *Yi et (199 *Pest 1997 *Jone	sley et al., astrointes yen, et al., helial grow 9-2119 (19 etnick et a HC and in al., "Kera 4).  navaria & \$7).	"Keratinocyte tinal tract," J. "Expression of the and differen 196).  "Insulin-depterferon-gamr tinocyte growt Stein, Pancrea 196, Honock, 29, Honock,	growth facilin. Investof keratin ntiation respondent on the control of the contro	ABO J., 12: 973-986 (1993). actor induces proliferation of hep est., 94: 1764-1777 (1994). ocyte growth factor in embryonic esulting in polycystic kidneys and diabetes mellitus induced in trans 52: 773-782 (1988). Induces pancreatic ductal epithelisth and Regeneration, Chapter 4, p. Res., 308-310 (1997).	atocytes liver of t dother or sgenic m ial prolife	and, ep ransgen gan mal ice by e	ithelial cells ic mice car formations ctopic expr	s throughout the uses changes in " Oncogene, 12 ession of class hol., 145: 80-85		
	C6 C7 C8 C9 C10	rat g *Nguy epith 2109 *Sarv III M *Yi et (199 *Pesh 1997 *Jone *Krak	sley et al., astrointes yen, et al., helial grow 9-2119 (19 etnick et a HC and in al., "Kera 4).  navaria & S7).  s & Sarve owski et al.	"Keratinocyte tinal tract," J. "Expression of the and differen 196).  "Insulin-depterferon-gament tinocyte growth 1960;  Stein, Pancrea 1961, 1962, J. End. 1962, J. End.	growth factor in the control of the	ABO J., 12: 973-986 (1993). actor induces proliferation of hep est., 94: 1764-1777 (1994). ocyte growth factor in embryonic esulting in polycystic kidneys and diabetes mellitus induced in trans. 52: 773-782 (1988). Induces pancreatic ductal epithelists and Regeneration, Chapter 4, p. Res., 308-310 (1997). Ty, 167-175 (1999).	atocytes liver of t dother or sgenic m ial prolife	and, ep ransgen gan mal ice by e	ithelial cells ic mice car formations ctopic expr	s throughout the uses changes in " Oncogene, 12 ession of class hol., 145: 80-85		
	C6 C7 C8 C9 C10 C11	rat g *Nguy epitr 2105 *Sarv III M *Yi et (199 *Pest 1997 *Jone *Krak *Kritz	sley et al., astrointes yen, et al., helial grow 9-2119 (19 etnick et a HC and in al., "Kera 4).  as & Sarve owski et al., 1	"Keratinocyte tinal tract," J. "Expression of the and differen 196).  al., "Insulin-depterferon-gampatinocyte growth Stein, Pancrea 11., 162, J. Ende 63, J. Endocrit	growth faction and the control of th	ABO J., 12: 973-986 (1993). actor induces proliferation of hep est., 94: 1764-1777 (1994). ocyte growth factor in embryonic esulting in polycystic kidneys and diabetes mellitus induced in trans. 52: 773-782 (1988). Induces pancreatic ductal epithelist and Regeneration, Chapter 4, p. Res., 308-310 (1997). gy, 167-175 (1999).	atocytes liver of t dother or sgenic m ial prolife	and, ep ransgen gan mal ice by e	ithelial cells ic mice car formations ctopic expr	s throughout the uses changes in " Oncogene, 12 ession of class hol., 145: 80-85		
	C6 C7 C8 C9 C10	rat g *Nguy epitr 2100 *Sarv III M *Yi et (199 *Pest 1997 *Jone *Krak *Kritz *Krak	sley et al., lastrointes yen, et al., helial grow 9-2119 (19 etnick et a HC and in al., "Kera 4). havaria & Sr). es & Sarve owski et al., 11 owski et al., 11 owski et al.	"Keratinocyte tinal tract," J. "Expression of the and differen 196).  al., "Insulin-depterferon-gampatinocyte growth Stein, Pancrea 11., 162, J. Ende 63, J. Endocrit	growth faction responds to the control of the contr	ABO J., 12: 973-986 (1993). Actor induces proliferation of hepest., 94: 1764-1777 (1994). Actor induces proliferation of hepest., 94: 1764-1777 (1994). Actor induces proliferation in embryonic esulting in polycystic kidneys and diabetes mellitus induced in transfer 52: 773-782 (1988). Anduces pancreatic ductal epithelicath and Regeneration, Chapter 4, 19. Res., 308-310 (1997). Actor of the property of the prope	atocytes liver of t dother or sgenic m ial prolife	and, ep ransgen gan mal ice by e	ithelial cells ic mice car formations ctopic expr	s throughout the uses changes in " Oncogene, 12 ession of class hol., 145: 80-85		
	C6 C7 C8 C9 C10 C11 C12	rat g *Nguy epith 2100 *Sarv III M *Yi et (199 *Pesh 1997 *Jone *Krak *Kritz *Krak	sley et al., lastrointes yen, et al., helial grow 9-2119 (19 etnick et al., 'Kera 4). havaria & S'). havaria & S'). havaria & Sarve owski et al., 'I owski et al., 'I owski et al., 'I owski et al., 'I owski et al., 'M	"Keratinocyte tinal tract," J. "Expression of the and differen 196). al., "Insulin-del terferon-gamr tinocyte growth 196, thick, 29, Honald, 162, J. Ende 63, J. Endecrial., 154(3), Am	growth factor in the control of the	ABO J., 12: 973-986 (1993). actor induces proliferation of hep est., 94: 1764-1777 (1994). ocyte growth factor in embryonic esulting in polycystic kidneys and diabetes mellitus induced in trans 52: 773-782 (1988). Induces pancreatic ductal epithelisth and Regeneration, Chapter 4, p. Res., 308-310 (1997). gy, 167-175 (1999). 23-530 (1999). Diogy, 683-691 (March 1999).	atocytes liver of t dother or sgenic m ial prolife	and, ep ransgen gan mal ice by e	ithelial cells ic mice car formations ctopic expr	s throughout the uses changes in " Oncogene, 12 ession of class hol., 145: 80-85		
	C6 C7 C8 C9 C10 C11 C12 C13 C14 C15	rat g *Nguy epitf 2100 *Sarv III M *Yi et (199 *Pest 1997 *Jone *Krak *Kritz *Krak *Eber *Wall *Tasu	sley et al., lastrointes yen, et al., helial grow 9-2119 (19 etnick et al., 14). havaria & 57). es & Sarve owski et al., 10 owski et al., 11, et al., 12, 12, 12, 14, et al., 13, 14, et al., 14, 15, 14, 15, 14, 15, 14, 15, 15, 16, 16, 16, 17, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18	"Keratinocyte tinal tract," J. "Expression of the and differen 196).  "In the state of the state	growth factor in the control of the	### ### ### ### ### ### ### ### ### ##	atocytes liver of t dother or sgenic m ial prolife	and, ep ransgen gan mal ice by e	ithelial cells ic mice car formations ctopic expr	s throughout the uses changes in " Oncogene, 12 ession of class hol., 145: 80-85		
	C6 C7 C8 C9 C10 C11 C12 C13 C14	rat g *Nguy epitf 2100 *Sarv III M *Yi et (199 *Pesh 1997 *Jone *Krak *Kritz *Krak *Eber *Wall *Tasu *Ham	sley et al., lastrointes yen, et al., helial grow 3-2119 (19 etnick et al., 'Kera 4). havaria & 57). es & Sarve owski et al., to owski et al., to owski et al., al., et al., J. ida, et al., J. ida, et al., mer, et al.	"Keratinocyte tinal tract," J. "Expression of the and differen 196).  al., "Insulin-del terferon-gamritinocyte growth 196, and 19	growth factor in the control of the	### ### ### ### ### ### ### ### ### ##	atocytes liver of t dother or sgenic m ial prolife	and, ep ransgen gan mal ice by e	ithelial cells ic mice car formations ctopic expr	s throughout the uses changes in " Oncogene, 12 ession of class hol., 145: 80-85		

Express Mail Label No.: EV 392154180 US Page 2 of 2

Date of Deposit: February 20, 2004

C18	*Mullins, et al., J. Clin. Invest., 97(7):1557-1560 (1996).
C13	**O'Reilly, et al., <i>Diabetes</i> , 46:599-606 (1997).
C14	**Fernandes, et al., <i>Endocrinol.</i> , 138:1750-1762 (1997).

<sup>\*</sup> copies of these references are not provided as they were previously cited by or submitted to the U.S. Patent Office in a prior application, **Serial No. 09/212,531**, **filed December 16**, **1998**, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

<sup>\*\*</sup> copies of these references are not provided as they were previously cited by or submitted to the U.S. Patent Office in a prior application, Serial No. 09/826,779, filed April 5, 2001, which is a Continuing Application of Serial No. 09/212,531, filed December 16, 1998, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Date Considered	
1	 	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1887751v1